Mallia Innovations Enhances Advisory Board with Key Appointments

Mallia Innovations GmbH, a leader in biopharmaceutical therapies for hair loss and wound healing, has appointed Jens Holstein, Dr. Alexandra Ogilvie, and Dr. Ulrich Dauer to its Advisory Board. The company aims to leverage their expertise in corporate finance, biotechnology, and dermatology to advance its sCD83-based therapies.

Jens Holstein, with extensive experience in the biopharmaceutical sector including a tenure at BioNTech, will support Mallia's financial growth strategies. Dr. Alexandra Ogilvie, a dermatologist, will contribute her clinical insights, addressing the need for innovative hair growth solutions. Dr. Ulrich Dauer brings significant experience in biotech entrepreneurship, ready to assist in translating scientific advances into therapies.

This strategic enhancement of the advisory board comes as Mallia continues to develop its proprietary sCD83 protein for cosmetic and therapeutic applications.